Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review
Abstract Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard trea...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2017-08, Vol.92, p.681-689 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 689 |
|---|---|
| container_issue | |
| container_start_page | 681 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 92 |
| creator | Anjum, Komal Shagufta, Bibi Ibtesam Abbas, Syed Qamar Patel, Seema Khan, Ishrat Shah, Sayed Asmat Ali Akhter, Najeeb Hassan, Syed Shams ul |
| description | Abstract Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays. |
| doi_str_mv | 10.1016/j.biopha.2017.05.125 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1906468446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0753332217318942</els_id><sourcerecordid>1906468446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-61e6410629b2f495f153472b3f21b2b7bcd7c4194395df285c6baca0b18979f83</originalsourceid><addsrcrecordid>eNqFkbuO1DAUhi0EYoeFN0DI5VJk8D0JBdIyggVpEQVQW45zzHpI4uDLonl7PJqBgobqNP9F_3cQek7JlhKqXu23gw_rndkyQtstkVvK5AO0ob0kjSKkfYg2pJW84ZyxC_QkpT0hRCrePUYXrJMdaxXZINiVGGHJOGWTS8JmGbEruUTA-Q6iWaFkb_EKMa1gs7-HhIPD3ycfhsmkHGaD5zJl70KcAV_dvP308uw8vMbXOMK9h19P0SNnpgTPzvcSfXv_7uvuQ3P7-ebj7vq2saLjuVEUlKBEsX5gTvTSUclFywbuGB3Y0A52bK2gveC9HF0dYdVgrCED7fq2dx2_RFen3DWGnwVS1rNPFqbJLBBK0rQnSqhOCFWl4iS1MaQUwek1-tnEg6ZEHwHrvT4B1kfAmkhdAVfbi3NDGWYY_5r-EK2CNycB1J11e9TJelgsjD5WgHoM_n8N_wbYyS_emukHHCDtQ4lLZaipTkwT_eX45OOPacsrBsH4bz_toz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1906468446</pqid></control><display><type>article</type><title>Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anjum, Komal ; Shagufta, Bibi Ibtesam ; Abbas, Syed Qamar ; Patel, Seema ; Khan, Ishrat ; Shah, Sayed Asmat Ali ; Akhter, Najeeb ; Hassan, Syed Shams ul</creator><creatorcontrib>Anjum, Komal ; Shagufta, Bibi Ibtesam ; Abbas, Syed Qamar ; Patel, Seema ; Khan, Ishrat ; Shah, Sayed Asmat Ali ; Akhter, Najeeb ; Hassan, Syed Shams ul</creatorcontrib><description>Abstract Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2017.05.125</identifier><identifier>PMID: 28582760</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Cannabinoids - pharmacology ; Cannabinoids - therapeutic use ; Cell Survival - drug effects ; Cell Survival - physiology ; Combined Modality Therapy - trends ; FDA approved drugs ; Forecasting ; GBM chemotherapy ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioblastoma - therapy ; Humans ; Internal Medicine ; Medical Education ; Natural anti-glioma ; Novel anti-glioma ; Synthetic anti-glioma ; Tumor Burden - drug effects ; Tumor Burden - physiology</subject><ispartof>Biomedicine & pharmacotherapy, 2017-08, Vol.92, p.681-689</ispartof><rights>Elsevier Masson SAS</rights><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-61e6410629b2f495f153472b3f21b2b7bcd7c4194395df285c6baca0b18979f83</citedby><cites>FETCH-LOGICAL-c483t-61e6410629b2f495f153472b3f21b2b7bcd7c4194395df285c6baca0b18979f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2017.05.125$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28582760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anjum, Komal</creatorcontrib><creatorcontrib>Shagufta, Bibi Ibtesam</creatorcontrib><creatorcontrib>Abbas, Syed Qamar</creatorcontrib><creatorcontrib>Patel, Seema</creatorcontrib><creatorcontrib>Khan, Ishrat</creatorcontrib><creatorcontrib>Shah, Sayed Asmat Ali</creatorcontrib><creatorcontrib>Akhter, Najeeb</creatorcontrib><creatorcontrib>Hassan, Syed Shams ul</creatorcontrib><title>Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Abstract Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabinoids - therapeutic use</subject><subject>Cell Survival - drug effects</subject><subject>Cell Survival - physiology</subject><subject>Combined Modality Therapy - trends</subject><subject>FDA approved drugs</subject><subject>Forecasting</subject><subject>GBM chemotherapy</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Natural anti-glioma</subject><subject>Novel anti-glioma</subject><subject>Synthetic anti-glioma</subject><subject>Tumor Burden - drug effects</subject><subject>Tumor Burden - physiology</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkbuO1DAUhi0EYoeFN0DI5VJk8D0JBdIyggVpEQVQW45zzHpI4uDLonl7PJqBgobqNP9F_3cQek7JlhKqXu23gw_rndkyQtstkVvK5AO0ob0kjSKkfYg2pJW84ZyxC_QkpT0hRCrePUYXrJMdaxXZINiVGGHJOGWTS8JmGbEruUTA-Q6iWaFkb_EKMa1gs7-HhIPD3ycfhsmkHGaD5zJl70KcAV_dvP308uw8vMbXOMK9h19P0SNnpgTPzvcSfXv_7uvuQ3P7-ebj7vq2saLjuVEUlKBEsX5gTvTSUclFywbuGB3Y0A52bK2gveC9HF0dYdVgrCED7fq2dx2_RFen3DWGnwVS1rNPFqbJLBBK0rQnSqhOCFWl4iS1MaQUwek1-tnEg6ZEHwHrvT4B1kfAmkhdAVfbi3NDGWYY_5r-EK2CNycB1J11e9TJelgsjD5WgHoM_n8N_wbYyS_emukHHCDtQ4lLZaipTkwT_eX45OOPacsrBsH4bz_toz0</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Anjum, Komal</creator><creator>Shagufta, Bibi Ibtesam</creator><creator>Abbas, Syed Qamar</creator><creator>Patel, Seema</creator><creator>Khan, Ishrat</creator><creator>Shah, Sayed Asmat Ali</creator><creator>Akhter, Najeeb</creator><creator>Hassan, Syed Shams ul</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170801</creationdate><title>Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review</title><author>Anjum, Komal ; Shagufta, Bibi Ibtesam ; Abbas, Syed Qamar ; Patel, Seema ; Khan, Ishrat ; Shah, Sayed Asmat Ali ; Akhter, Najeeb ; Hassan, Syed Shams ul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-61e6410629b2f495f153472b3f21b2b7bcd7c4194395df285c6baca0b18979f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabinoids - therapeutic use</topic><topic>Cell Survival - drug effects</topic><topic>Cell Survival - physiology</topic><topic>Combined Modality Therapy - trends</topic><topic>FDA approved drugs</topic><topic>Forecasting</topic><topic>GBM chemotherapy</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Natural anti-glioma</topic><topic>Novel anti-glioma</topic><topic>Synthetic anti-glioma</topic><topic>Tumor Burden - drug effects</topic><topic>Tumor Burden - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anjum, Komal</creatorcontrib><creatorcontrib>Shagufta, Bibi Ibtesam</creatorcontrib><creatorcontrib>Abbas, Syed Qamar</creatorcontrib><creatorcontrib>Patel, Seema</creatorcontrib><creatorcontrib>Khan, Ishrat</creatorcontrib><creatorcontrib>Shah, Sayed Asmat Ali</creatorcontrib><creatorcontrib>Akhter, Najeeb</creatorcontrib><creatorcontrib>Hassan, Syed Shams ul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anjum, Komal</au><au>Shagufta, Bibi Ibtesam</au><au>Abbas, Syed Qamar</au><au>Patel, Seema</au><au>Khan, Ishrat</au><au>Shah, Sayed Asmat Ali</au><au>Akhter, Najeeb</au><au>Hassan, Syed Shams ul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>92</volume><spage>681</spage><epage>689</epage><pages>681-689</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Abstract Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>28582760</pmid><doi>10.1016/j.biopha.2017.05.125</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 2017-08, Vol.92, p.681-689 |
| issn | 0753-3322 1950-6007 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1906468446 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain Neoplasms - therapy Cannabinoids - pharmacology Cannabinoids - therapeutic use Cell Survival - drug effects Cell Survival - physiology Combined Modality Therapy - trends FDA approved drugs Forecasting GBM chemotherapy Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma - therapy Humans Internal Medicine Medical Education Natural anti-glioma Novel anti-glioma Synthetic anti-glioma Tumor Burden - drug effects Tumor Burden - physiology |
| title | Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A41%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20and%20future%20therapeutic%20perspectives%20of%20glioblastoma%20multiforme%20(GBM)%20therapy:%20A%20review&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Anjum,%20Komal&rft.date=2017-08-01&rft.volume=92&rft.spage=681&rft.epage=689&rft.pages=681-689&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2017.05.125&rft_dat=%3Cproquest_cross%3E1906468446%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1906468446&rft_id=info:pmid/28582760&rft_els_id=1_s2_0_S0753332217318942&rfr_iscdi=true |